GRENOBLE, France--(BUSINESS WIRE)-- CEA-Leti and Capsum today announced that the successful transfer of Letis patented Lipidots nanovector technology to Capsum for cosmetic applications has produced the first commercial use of the new technology. Lipidots is a versatile nano-delivery platform based on tiny droplets of oil for encapsulating and carrying drugs or fluorescent imaging agents to targeted cells in the body for treatment or diagnosis. Letis partnership with Capsum shows that the technology is easily adapted for applications in the cosmetics industry. Capsum adapted the Lipidots technology for its NeoGoutttesTM, nano-emulsions that are used as a component in finished products and that provide a very efficient way of vectorizing lipophilic or hydrophilic concentrates of active ingredients. The nanovector encapsulation protects active ingredients, so they are conveyed through the skin for optimal effect. Technology transfer to our partners for commercialization of our research results is a critical part of Letis mission, said Patrick Boisseau, head of Letis nanomedicine program. The success of our project with Capsum demonstrates that the Lipidots nanovector technology can be scaled up from laboratory to industrial production easily and efficiently, and that it is well suited for a non-medical application like cosmetics. Capsum is focused on providing innovative … Continue reading →

St. Louis, MO (PRWEB) October 22, 2013 Two physicians from NeoSpine recently performed an innovative stem cell injection procedure on a patients spine to treat back pain caused by degenerative disc disease, the first one in the state of Washington. Dr. Richard Rooney and Dr. Kathy Wang, performed the successful pioneering procedure at Microsurgical Spine Center, the Northwests leading ambulatory surgery center located just outside of Seattle, Washington. At the forefront of medicine, stem cells use the bodys own healthy cells with the goal to regenerate to repair diseased spinal tissue. With stem cell treatment, bone marrow is extracted from the patients pelvis bone and is centrifuged to separate the stem cells from the other bone marrow components. The advanced separation and concentration process was developed by our partner, Celling Biosciences, explained Dr. Rooney. The extracted stem cells are injected directly into the patients affected discs, and the procedure is image guided for complete accuracy. We use the patients own cells in order to speed up the healing process, added Dr. Wang. Working with patients to find the root of their back pain, the stem cell injection is part of an overall treatment plan that includes an anti-inflammatory diet, and … Continue reading →

Category: Investment, Biotech, Pharma Stem Cell Stock Alert: BioRestorative (OTCBB: BRTX) Engages Consulting Firm to Advance brtxDISC Program Delivery Device through FDA Clearance Process JUPITER, Fla. - September 30, 2013 (Investorideas.com Newswire) BioRestorative Therapies Inc. ("BRT" or the "Company") (OTCQB: BRTX), a life sciences company focused on developing stem cell-based therapies for personal medical applications, announced the engagement of the regulatory consultancy firm Phil Triolo and Associates, LC ("PTA") to help advance the Company's brtxDISC therapeutic procedure through the U.S. Food and Drug Administration ("FDA") regulatory process. The brtxDISC program is the Company's non-surgical investigative treatment for bulging and herniated lumbar discs. Under the engagement, PTA will assist the Company in its efforts to obtain U.S. regulatory approval and to satisfy FDA regulations applicable to the Company's medical device used in the brtxDISC procedure, including the implementation of quality systems procedures. In addition, PTA will assist BRT in its efforts to satisfy FDA regulations relevant to the combination products (biologic plus device) it ultimately plans to commercialize in the U.S. PTA is also available to assist in any international regulatory approval processes the Company may pursue. "This is an important step in advancing the development of our brtxDISC procedure," said … Continue reading →

Researchers at UNC School of Medicine have discovered a potential environmental cause of autism in a type of chemotherapy drug, and they are beginning to investigate the effects of other non-chemo drugs that work by a similar mechanism. Professors Mark Zylka and Benjamin Philpot made the discovery while studying a drug thats effective against cancer, but also shows potential as a treatment for a genetic disease called Angelman syndrome. In the process, they made some new observations that seem to point to a cause of autism. Thats science, says Zylka. Youre trying to do something and you find something else. The duo, along with colleagues at UNC Chapel Hill and the University of Connecticut, published their results in the journal Nature on Aug. 28. On Sept. 30, the National Institutes of Health awarded Zylka a Pioneer Award to continue the autism work. Only about a dozen researchers receive the annual award, which provides up to $2.5 million over five years. According to the NIH website, the award supports researchers of exceptional creativity, who propose pioneering and possibly transforming approaches to major challenges in biomedical and behavioral research. Zylka and Philpot are both associate professors in the department of cell biology … Continue reading →